Abstract 307P
Background
Lacrimal gland is an exocrine secretory gland located at the upper temporal fossa of the orbit. It is part of the tear-forming apparatus that constitutes an important orbital structure. However, data available about tumors possibly originating in this site are scarce. In this study, we aimed to spotlight on this rare type of malignancy using the using data from American National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program.
Methods
We used SEER*Stat version 8.3.4, Microsoft Excel, as well as SPSS IBM SPSS Statistics for Windows, Version 21.0. In SEER*Stat, we used the (Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2015 Sub (1973-2013 varying)) database. We included SEER 18 cases that were diagnosed after 2003 (2004+) in which the primary site was identified as (C69.5 – Lacrimal gland). Only cases with malignant behavior, known age, and those in the Research Database were included.
Results
A total of 491 cases were identified with a median age of 63. Females represented the majority of the analyzed cohort (n = 263, 53.6%). Lacrimal gland tumors were most common among the white race (n = 376, 76.6%). Age-adjusted Incidence rate was 0.6 per 1,000,000 with a median survival of 41 months, while 5-year relative survival was 88.4% (CI: 81.9% - 92.6%). The most common pathology of studied cases was Non-Hodgkin lymphoma (n = 254, 51.7%) (Table).Table:
307P Different pathological subtypes for lacrimal gland tumours
Pathological Subtype | N. | % |
---|---|---|
NHL-Mature B-Cell Lymphomas | 254 | 51.7 % |
Squamous Cell Neoplasms | 71 | 14.5 % |
Adenomas &Adenocarcinomas | 64 | 13.0 % |
Malignant Lymphomas, NOS Or Diffuse | 32 | 6.5 % |
Mucoepidermoid Neoplasms | 17 | 3.5 % |
Epithelial Neoplasms, NOS | 10 | 2.0 % |
Nevi Melanomas | 8 | 1.6 % |
Ductal & Lobular Neoplasms | 7 | 1.4 % |
Lymphoid Leukemias (C42.1) | 6 | 1.2 % |
Transitional Cell Papillomas & Carcinomas | 4 | 0.8 % |
Complex Mixed & Stromal Neoplasms | 4 | 0.8 % |
Myomatous Neoplasms | 3 | 0.6 % |
Basal Cell Neoplasms | 2 | 0.4 % |
Complex Epithelial Neoplasms | 2 | 0.4 % |
Plasma Cell Tumors | 2 | 0.4 % |
Unspecified Neoplasms | 1 | 0.2 % |
Cystic, Mucinous & Serous Neoplasms | 1 | 0.2 % |
Fibromatous Neoplasms | 1 | 0.2 % |
Hodgkin Lymphomas | 1 | 0.2 % |
Nhl-Mature T & Nk-Cell Lymphomas | 1 | 0.2 % |
Conclusions
Lacrimal gland tumors are extremely rare with incidence rate of 0.6 per million. These tumors are more likely to occur in old age, females, white race. 5-years relative survival is 88.4% with a median survival of 41 months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract